Toxicology Testing

$696 billion
>3% U.S. GDP estimated cost of the opioid crisis in 2018

Source: Council of Economic Advisers (CEA)

$2.5 trillion
Cost of opioid crisis in U.S. 2015-2018

Source: Council of Economic Advisers (CEA)

3.5 million people
U.S. residents addicted to prescription opiates, 2019

Source: National Survey on Drug Use and Mortality

Testing Saves Lives

Medication-Assisted Treatment (MAT) reduced opioid overdose deaths by 59%*. MAT programs require intensive patient monitoring including drug screening to:

  • Ensure patient takes what is prescribed
  • Deter and detect misuse of dangerous drugs
Limitations of Current Common Urine-based Toxicology-testing Methods
  • Compliance with requirements for same-gender observation of sample collection is a burden
  • The potential for sample tampering
  • Delayed reporting of lab results

Evanostics’ Toxicology-testing Product

Evanostics’ toxicology-testing product combines an oral-fluid collection with a digital point-of-care test to detect 10 drug classes from a single collection. This product has been field-tested in a clinic.

Features & Benefits

Strategic Partner
NMS Labs is partnering with Evanostics on the drug-testing solution.

For 50 years, the company has been an established leader of laboratory diagnostics and forensic laboratory science. NMS Labs monitors relevant emerging test targets to identify new illicit drugs. This timely input will ensure that the Evanostics drug-testing product can stay ahead of the curve with an up-to-date assay menu.

Want more information?

Limitations of Current Swab-based Testing Methods
  • Collection is uncomfortable and inconvenient for the patients and healthcare workers
  • Typically requires a healthcare professional, limiting availability of the test
  • Healthcare professionals are exposed to a high risk of contracting the virus
Evanostics’ Respiratory Health Monitoring Product

The Evanostics product combines an oral-fluid, self-collection cartridge with a point-of-care instrumented test to detect multiple respiratory diseases from a single collection. This product tests for Covid-19 and influenza A & B. The product is in the development phase.

Features & Benefits

CONTACT US to learn more about our respiratory health product, and potentially partner in its development

Other Applications

Evanostics technology allows for new test targets to be easily added creating different cartridges. The cartridges can be run using the same analyzer opening new markets.

Different cartridges, same analyzer

  • Contained oral fluid collection
  • No sample preparation
  • Minimal training needed to run the test

We welcome inquiries from potential partners. If you have an Laboratory Developed Test and need a point-of-care platform partner, CONTACT US